



# *Divi's Laboratories Limited*

Date: September 26, 2023

To  
The Secretary  
**National Stock Exchange of India Limited**  
Exchange Plaza,  
Bandra-Kurla Complex, Bandra (East)  
**MUMBAI – 400 051**

**Stock Code: DIVISLAB**

To  
The Secretary  
**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street  
**MUMBAI – 400 001**

**Stock Code: 532488**

Dear Sir/ Madam,

**Sub: Press Release - USFDA Delegation visits the Company's Unit I at Choutuppal, Telangana, India**

Please find the enclosed press release regarding USFDA Delegation visit to the Company's Unit I at Choutuppal, Telangana, India on September 26, 2023.

This is for your information and records.

Thanking You,

Yours Faithfully,  
For **Divi's Laboratories Limited**

**M. Satish Choudhury**  
**Company Secretary & Compliance Officer**



26-Sep-2023

*Divi's Laboratories Limited*

## PRESS RELEASE

# USFDA Delegation Visits Divi's Choutuppall Facility



HYDERABAD, India - Divi's Laboratories Limited is delighted to announce that a high-level delegation from the U.S. Food and Drug Administration (USFDA), including Commissioner Dr. Robert M. Califf, India Country Director Dr. Sarah McMullen, and other officials, visited the company's manufacturing facility in Choutuppall, Telangana, India.

The delegation's visit covered a wide range of topics, reflecting the dynamic landscape of the Active Pharmaceutical Ingredient (API) industry, the integration of new technologies, sustainable practices in chemistry, raising manufacturing standards, and ensuring the availability of APIs. The company showcased its large-scale world-class production facilities, advanced automated manufacturing capabilities, commitment to innovation, and its crucial role in investing in new technologies to ensure a consistent supply of high-quality APIs.

Divi's Laboratories Limited is a globally recognized pharmaceutical manufacturing company known for its commitment to quality and large-scale manufacturing. With a global presence in supplying APIs to more than 100 countries, the company's unwavering commitment to compliance and sustainability sets it apart in the pharmaceutical industry.

"We are proud to participate in this important visit to share our role as a reliable API manufacturer that can deliver large quantities in a relatively short time," stated Dr. Kiran S Divi, CEO of Divi's Laboratories Limited. "We look forward to continuing to engage and be a part of addressing critical issues that affect the worldwide pharmaceutical industry."